National Defense Authorization Act, NDAA Conference Committee

The version of the National Defense Authorization Act (NDAA) passed September 18, 2017 by the Senate prohibits funding for medical research by DoD unless such research meets very narrowly defined criteria and places unnecessary and burdensome red-tape, acquisition, compliance and auditing requirements on research programs within the Department of Defense. The troublesome portions of the Senate version of the NDAA are Sections 733, 891, 892, and 893. 

I functioned as a reader (evaluator) in 2016 for MSRP Grant Applications and am a Veteran with a Multiple Sclerosis diagnosis (one of 20,000 veterans know to the VA with the diagnosis). We need the, "High Risk/High Reward" research the Congressionally Directed Medical Research Program (CDMRP) and the Multiple Sclerosis Research Program (MSRP) bring to the table in the ongoing effort to: STOP MS PROGRESSION, RESTORE PATIENT'S LOST FUNCTION and END MS FOREVER.   

I will call on each member of the NDAA Conference Committee to support striking Sections 733, 891, 892, and 893 of the Senate's NDAA Bill in any final version of the NDAA.

Stay tuned for more updates on this subject.